Dublin, June 04, 2024 (GLOBE NEWSWIRE) -- The "Dry Powder Inhaler Global Market Report 2024" has been added to ResearchAndMarkets.com's offering. The dry powder inhaler market size has grown strongly ...

Results showed that a dry powder inhaler loaded with umeclidinium and vilanterol produced a 14% lower risk of moderate or severe COPD flare-ups, compared to a metered-dose inhaler loaded with ...

The Dry Powder Inhaler Market is poised for significant growth, with a market value of USD 20.83 billion in 2024, projected to climb to USD 29.95 billion by 2034, representing a steady CAGR of 3.70% ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are ...

The dry powder inhaler market is projected to be worth USD 20.83 billion in 2024. The market is likely to reach USD 29.95 billion by 2034. The Industry is expected to surge at a CAGR of 3.70% from ...

Regulatory pressures and changes in the drug delivery market have driven the innovation of the dry powder inhaler forward. Request a Sample Copy of this Report Now! According to the World Health ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Please provide your email address to receive an email when new articles are posted on . Almost all of the estimated 1.15 MMT of CO 2 equivalent emissions in 2022 came from metered-dose inhalers. The ...

Investing.com -- MannKind Corporation (NASDAQ:MNKD) shares fell 37% Wednesday after partner United Therapeutics unveiled a soft-mist inhaler that will compete with dry powder inhalation therapies.